Lupus

April 02, 2021

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending April 2, 2021.

April 01, 2021

While some patients with systemic lupus erythematosus (SLE) find it beneficial to receive anti-inflammatory therapy to treat their fatigue, there is increasingly more evidence that chronic diseases increase risk of psychiatric disorders, such as anxiety and depression, which need to be treated differently.

March 25, 2021

Patients with inflammatory rheumatic diseases (IRD) may be more likely to acquire severe pneumonia due to COVID-19, especially in patients with autoimmune disease who are being treated with rituximab.

March 24, 2021

Currently, diagnosing a patient with systemic lupus erythematosus (SLE) is a complex process that compares potential lupus with other conditions. It can be challenging and delayed by a period of time, which increases patient uncertainty, referrals, healthcare utilization, increased flares, and organ dysfunction. In this study, machine learning (ML) via artificial intelligence tools based on patient data was used to develop an algorithm to help with SLE diagnosis.

March 05, 2021

Brian Skaggs, PhD, and Maureen McMahon, MD, sat down with Rheumatology Network to discuss the results of their longitudinal study, “A Panel of Biomarkers Associates With Increased Risk for Cardiovascular Events in Women With Systemic Lupus Erythematosus.”

March 01, 2021

In the second portion of this series, Dr. Concoff discusses the path forward in the evaluation and treatment of systemic lupus erythematosus (SLE).

February 24, 2021

Investigators explored the connection between patients with systemic lupus erythematosus (SLE) and an increased risk of asthma and chronic obstructive pulmonary disease (COPD), which concurrently correlated with worse patient-reported outcomes (PROs) cross-sectionally.

January 25, 2021

Voclosporin (LUPKYNIS), in combination with an existing immunosuppressive therapy regimen, works to safely and effectively treat adult patients with lupus nephritis.

January 25, 2021

Alyssa Johnsen, MD, PhD, shares her insight on the importance of understanding key pathways that drive immune-mediated diseases, which can help rheumatologists develop more potent and specific therapies for patients with rheumatic disease.

January 11, 2021

The reviewers find persistent disease activity and flares despite progress to date. In addition, they point to the persistence of glucocorticoid treatment dependency, comorbidity burden, reduced health-related quality of life, and inconsistent access to high-quality care.